問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

Division of Hematology & Oncology

Taipei Veterans General Hospital (在職)

Division of Thoracic Medicine

Digestive System Department

Division of General Internal Medicine

Division of Hematology & Oncology

National Health Research Institutes (在職)

Division of General Internal Medicine

Taipei Venterans General Hospital Taoyuan Branch

Division of Hematology & Oncology

更新時間:2023-09-19

姜乃榕
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

144Cases

2017-11-01 - 2021-05-20

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated9Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2025-08-25 - 2026-12-25

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-04-11 - 2021-09-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

2018-07-30 - 2020-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting6Sites

Terminated1Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2025-09-01 - 2030-06-30

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2026-09-01 - 2029-03-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2017-03-23 - 2019-03-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

李重賓
Taipei Veterans General Hospital

Digestive System Department

2016-05-01 - 2020-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

2023-11-16 - 2027-01-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites